Quarterly ResultNov 4, 2026, 04:17 PM
Revolution Medicines Reports $197.6M Revenue, $1.51B Net Loss
AI Summary
Revolution Medicines, Inc. reported its quarterly results for the period ending September 30, 2026. The company generated $197.6 million in product revenue for the nine months ended September 30, 2026, marking its first significant revenue generation following the August 2026 launch of RASONQUE®. Despite the new revenue stream, the company reported a net loss of $1.51 billion for the same period, an increase from the previous year, driven by substantial investments in research and development and selling, general, and administrative expenses. The company's cash position improved, with cash and cash equivalents reaching $615.9 million.
Key Highlights
- Revolution Medicines reported $197.6M in product revenue for the nine months ended Sep 30, 2026, a significant increase from $0 in the prior year period.
- Total revenue reached $197.6M for the nine months ended Sep 30, 2026, compared to $0 for the same period in 2025.
- Net loss for the nine months ended Sep 30, 2026, was $1.51B, compared to $766.4M in the prior year period.
- Research and development expenses increased to $1.16B for the nine months ended Sep 30, 2026, from $692.4M in the prior year period.
- Selling, general and administrative expenses rose to $364.8M for the nine months ended Sep 30, 2026, from $128.4M in the prior year period.
- Cash and cash equivalents stood at $615.9M as of Sep 30, 2026, up from $383.7M as of Dec 31, 2025.
- Total assets grew to $4.30B as of Sep 30, 2026, from $2.35B as of Dec 31, 2025.
Price Impact
More from RVMD